Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit
George Washington University law professor Jonathan Turley pointed out Tuesday the irony surrounding Colorado’s legal battles over conversion therapy, calling...